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In this study, the aim was to provide observational data from an ascent to the summit of Mount Damavand (5670 meters above sea
level (m.a.s.l), Iran) by a group of people with type 1 diabetes (T1DM), with a focus on their physiological characteristics. After a 3-
day expedition, 18 T1DM patients, all treated with personal insulin pumps, successfully climbed Mount Damavand. Information
was collected on their physiological and dietary behaviors, as well as medical parameters, such as carbohydrate consumption,
glucose patterns, insulin dosing, and the number of hypo- and hyperglycemic episodes during this time frame. The participants
consumed significantly less carbohydrates on day 3 compared to day 1 (16.4 vs. 23.1 carbohydrate units; p = 0:037). Despite this,
a gradual rise in the mean daily glucose concentration as measured with a glucometer was observed. Interestingly, the patients
did not fully respond to higher insulin delivery as there was no significant difference in mean daily insulin dose during the
expedition. There were more hyperglycemic episodes (≥180mg/dL) per patient on day 3 vs. day 1 (p < 0:05) and more severe
hyperglycemic episodes (>250mg/dL) per patient on days 2 (p < 0:05) and 3 (p < 0:05) vs. day 1. In summary, high mountain
trekking is feasible for T1DM patients with good glycemic control and no chronic complications. However, some changes in
dietary preferences and an observable rise in glucose levels may occur. This requires an adequate therapeutic response.
1. Introduction
The American Diabetes Association recommends that people
with type 1 diabetes mellitus (T1DM) should be able to partic-
ipate in all forms of sports consistent with their desires and
goals [1]. As a result of the recent progress in T1DM treatment
and monitoring, the number of patients undertaking extreme
sports activities has been constantly growing. This includes
individuals practicing high mountain trekking. However,
research data on their physiological performance as well as
health benefits and risks are very limited, and not many
clinical recommendations exist in this field [1–8]. This is
associated with the fact that very few T1DM patients have been
observed at high altitudes for their physiologic, pathophysio-
logic, and diabetic management, so far. More data on high
altitude physiology in patients with diabetes could help provide
diabetic-specific guidelines and make a conscious decision
about climbing to a high altitude. This could be essential when
proposing recommendations concerning diet, insulin therapy,
and acclimatization, a process that involves many short- and
long-term physiological adaptations occurring to maintain
oxygen balance in response to altitude exposure [3, 9]. It is
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unknown what kinds of changes are necessary in diabetes
management strategies during trekking at extreme altitudes
(over 5500m.a.s.l.). In such conditions, increased physical
activity may both reduce insulin requirements and cause an
altitude-induced rise in counter-regulatory hormone concen-
tration, potentially increasing insulin resistance.
Before trekking, T1DM patients should take into account
many other potential problems, such as the effect of delayed
absorption of carbohydrate at mealtime, dehydration, high
levels of exertion, psychological stress, suppressed appetite,
risk of insulin freezing, decreased effectiveness of glucagon
owing to possible body glycogen store depletion, uninten-
tional insulin delivery from the insulin pump due to reduced
barometric pressure, and many others [1, 3, 5]. One may also
hypothesize that existing retinopathy may worsen with the
rise of physiological demands for oxygen and its reduced
pressure during high-altitude trekking. However, current
literature indicates that patients who have no diagnosed
complications do not appear to be at a substantial risk for
developing new diabetes-related complications [3]. T1DM
patients with microvascular complications who wish to
undertake travel at altitude should undergo a medical evalu-
ation of conditions that might increase exercise-associated
risk; this includes medical history, physical examination,
retinal examination, resting/exercise ECG, and/or pulmo-
nary assessments [3]. However, it is of scientific and clinical
importance to provide more data in this field [10].
We have previously reported an ascent to Mount Dama-
vand (5670m.a.s.l.), the highest peak in Iran, by a group of
T1DMpatients, as well as their performance on insulin pumps
during that event [11]. Here, we present further observational
data collected during our Damavand expedition, with a focus
on the participants’ physiological characteristics.
2. Materials and Methods
The study was approved by the Local Bioethical Committee.
Patients have given their informed consent for the participa-
tion in this study.
Our group consisted of individuals with a diverse baseline
level of physical activity. There were 4 participants who had
completed the “Butchers race” (an 84km mountain mara-
thon) two months prior to the current expedition, but some
others had a baseline physical activity comparable to the
general population. This group had some previous experience
in high mountain climbing (Alps, 3000m.a.s.l.) [6]. Basic data
related to our 2016 Damavand expedition included the
patients’ characteristics, glycemic control, and pump function-
ing, as well as safety issues [11]. In short, Mount Damavand
was ascended within 3 days by a group of 19 individuals (17
men, 2 women) all diagnosed with T1DM and treated with a
personal insulin pump. They were at a mean age of 32.5 years
(range, 23–48 years), had a mean body mass index of
23.8kg/m2 (range, 19.7–30.2kg/m2), a mean HbA1c level of
6.6% (range, 5.9–7.1%), and a mean diabetes duration of
12.6 years (range, 3–29 years).
All patients were using the blood glucometers that are
recommended for their current pump (Accu-Chek Performa
Combo (4 patients) (Roche Diagnostics), Contour Link (7),
Contour Plus Link 2.4 (7), and Contour Plus (1) (Bayer
HealthCare LLC, Diabetes Care). Registration conditions (alti-
tude, temperature, and humidity) for each device used in our
study were summarized earlier [6]. The patients were given
meals rich in carbohydrates, and no protein or fat meals were
recommended. They spent one night at the Polour Resort, Iran
(altitude: 2270m.a.s.l.), after which they drove to Goosfand-
Saran (altitude: 3200m.a.s.l.), where they began their ascent
to the shelter (4200m.a.s.l., 1930m altitude difference, 6h of
trekking). On day 2, the group climbed to 4700m.a.s.l. to accli-
mate to the altitude (3h) and returned to the shelter
(4200m.a.s.l., 500m altitude difference, 5h of trekking). On
day 3, 18 T1DM patients decided to challenge the mountain
and after 9.5 hours of climbing reached the peak around
11:40 a.m. (1470m altitude difference, 15h of trekking).
The following data was collected on the participants’
physiological characteristics and dietary behaviors, as well
as medical parameters: carbohydrate and fluid consumption,
glucose patterns, insulin dosing, number of hypo- and hyper-
glycemic episodes, blood oxygen saturation, and blood
ketone and lactate concentration. A hypoglycemia episode
was defined as blood glucose < 70mg/dL (3.9mmol/L), while
hyperglycemia as blood glucose ≥ 180mg/dL (10mmol/L).
Additionally, the threshold for severe hyperglycemia was
set at 250mg/dL (13.9mmol/L). Glucose fluctuations were
primarily assessed with blood glucometers. Measurements
documenting episodes of hypo- or hyperglycemia within
30-minute periods were counted as one event. All patients
were using glucometers recommended for their pumps. They
were advised to establish their blood glucose concentrations
with the use of glucometers at least 8 times per day: before
breakfast and every 1–1.5 hours during breaks and before
meals; if needed, additional measurements could be per-
formed. There were 10 (52.5%) T1DM patients using CGM
(Medtronic with Enlite sensor 2) and 11 (57.8%) using
FGM (FreeStyle Libre technology, Abbott Diabetes Care);
among them, 4 were using both systems [11]. As our patients
used two different monitoring systems, we decided to assess
blood glucose concentrations primarily with glucometers.
Baseline glucose data were previously described [11]. In the
present paper, we provide further detailed information,
comparing the 3 expedition days.
We also estimated acute mountain sickness (AMS) on a
scale which evaluated the negative health effects of high
altitude, caused by rapid exposure to low amounts of oxygen.
Symptoms may include headaches, vomiting, fatigue, trouble
with sleeping, and dizziness. Additionally, the Borg scale was
used as a method of subjectively rating perceived exertion on
the basis of physical signs such as heart rate, breathing rate,
and perspiration on a scale of 0–10.
In the paper, we focused on the differences between the 3
days of the expedition using the Borg and AMS scales [10].
We measured lactate blood concentrations at the beginning
of the day, i.e., directly before trekking started, and at the
highest altitude achieved during the day, up to 5 minutes
after reaching the highest point (Lactate Scout, EKF-
Diagnostics; registered to work at temperatures ranging from
5°C to 45°C, at 10–85% humidity, and up to an altitude of
4000m.a.s.l., as per the instruction manual). Ketone blood
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concentration was also examined at the highest altitude
achieved during the day.
To approximate a baseline fitness, a few weeks before the
expedition, VO2 peak (peak oxygen uptake) was assessed in
13 T1DM patients. We applied a running treadmill (Saturn,
HP Germany) test (speed: 6.2 km/h, where at 3-minute inter-
vals, the inclination was increased: 3, 6, 9, 12, 15, 18, 21, and
24°) until the patient was unable to continue due to exhaustion.
We used the following devices: a K4b2 analyzer (Cosmed,
Italy), a biochemical analyzer Reflotron Plus (Roche, France),
a lactate analyzer Biosen S-line (EKF, Germany), and a body
composition analyzer (BIA101 Anniversary). VO2 peak in
mL/kg/min occurring at peak exercise was used to define the
subject’s aerobic capacity and expressed as the mean value
during the last 1min of the test [12].
No preventive medication to assist acclimatization was
used.
Statistically significant differences were set by ANOVA.
To make pairwise comparisons between days, we applied
the pairwise t-test with the Bonferroni correction (p < 0:05).
Statistical analyses were performed with R 3.6.1 statistical
software. The Shapiro-Wilk test served to assess the normal-
ity of distribution.
3. Results
The observational data collected from all the 19 T1DM
participants are summarized in Table 1. During the entire
trek, the mean fluid consumption was 2–2.4 L per day, with
no significant differences between the expedition days.
However, the T1DM patients consumed significantly less
carbohydrates on day 3 compared to day 1 (16.4 vs. 23.1
carbohydrate units (1 carbohydrate unit = 10 g of digestible
carbohydrates), p = 0:037 in post hoc analysis).
Despite the drop in carbohydrate consumption (day 3 vs.
day 1, p < 0:05), a rise in mean daily glucose concentration as
measured with a glucometer was observed (Figure 1). Inter-
estingly, the patients did not fully respond to a higher insulin
delivery as there was no significant difference in the mean
daily insulin dose during the expedition. There were more
hyperglycemic episodes per patient on day 3 vs. day 1 (4.8
vs. 2.1, p < 0:05) and more severe hyperglycemic episodes
per patient on days 2 (1.8, p < 0:05) and 3 (1.7, p < 0:05) vs.
day 1 (0.6) (Table 1). Similar to the glucometer results, the
CGM/FGM system data showed significant differences
between the expedition days, documenting a gradual increase
in blood glucose concentration (Table 1).
The results of the Borg test scale revealed that the per-
ceived exertion was significantly higher at the beginning of
days 2 (p = 0:0125) and 3 (p = 0:0039) vs. day 1. The perceived
exertion at the highest altitude achieved during the day was
significantly higher on day 3 compared to day 1 (p = 0:0134)
and day 2 (p = 0:0008). There was no correlation between
baseline physical fitness and the Borg scale results. AMS symp-
toms at the beginning of the day were significantly more
intense on day 2 (p = 0:0001) and day 3 (p = 0:0004) vs. day 1.
The blood oxygen saturation measured at the beginning
of the day was slightly higher on day 1 than on day 2
(p = 0:0017). The blood oxygen saturation measured at the
highest altitude reached during the day gradually decreased
with the statistically lowest value on day 3 vs. day 1
(p ≤ 0:0001) and day 2 (p ≤ 0:0001).
There was a numerical increase in mean lactate concen-
tration at the beginning of each of the following days in an
absolute value, but no statistical difference was observed. A
positive correlation was established between lactate concen-
tration at the beginning of day 2 and mean glucometer
glycemia on day 2 (p = 0:017, r = 0:55; Figure 2). No such
correlation was revealed for day 1 or 3 or for lactate concen-
tration at the highest altitude achieved during the day.
The baseline VO2 peak equaled 44:9 ± 4:1mL/kg/min. In
accordance with Astrand [13], the VO2 peak was classified as
very good in 2 cases, as good in 2 cases, as average in 6 cases,
as poor in 2 cases, and as very poor in 1 case. There was no
correlation between baseline fitness capacity and lactate con-
centration, Borg scale results, or mean glycemia as measured
with a glucometer across the 3 expedition days.
4. Discussion
In this observational study, we summarized the physiological
data of a group of T1DM patients during a high trekking
Damavand expedition. A significant rise in glucose concen-
tration with higher altitudes reached was observed; however,
this was not associated with a higher insulin delivery by
T1DM patients. Additionally, it was observed that a
reduction in carbohydrate consumption occurred on the
subsequent expedition days.
Some of our findings are in line with two earlier studies
reporting a loss of appetite and higher glucose concentrations
at higher altitudes [1, 14]. It has been suggested that transient
hyperglycemia occurs during short-term exposure to high
altitude, whereas long-term exposure results in lower plasma
glucose concentrations [14]. Most studies reported incre-
ments in insulin requirement at higher altitudes in patients
with T1DM [15–17]. Increased insulin requirements despite
exercise were also shown at extreme altitudes [18]. In addi-
tion, a positive correlation between AMS symptoms and
insulin requirements was observed [14].
The observed diabetes management inertia contributing
to hyperglycemia among our patients could be potentially
explained by the perceived exertion, which increased
together with the altitude reached. It was also postulated that
the stress response to high altitude dominates exercise-
enhanced insulin sensitivity, resulting in relative hyperglyce-
mia [19]. Of interest, the rise in glucose concentration could
not be fully explained by the rise in lactate concentration
alone, as the positive correlation was found only for day 2.
Thus, some other factors, like AMS and decreased blood
oxygen saturation, could have also contributed.
The high baseline level of lactate in our study group
requires further comments. One possible explanation is a
lack of appropriate acclimatization of our patients and subse-
quent hypoxia on the tissue level. This shortened acclimatiza-
tion period occurred due to the delayed arrival to Iran and
probably had an impact on the observed results. Some other
studies showed that if the exposure to high altitude was
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sufficiently long, lactate responses to exercise return to those
seen at a sea level [20].
On the molecular level, a phenomenon contributing to the
increased lactate levels observed at higher altitudes might be
increased membrane cotransporters for lactate induced by
physical activity [21]. This could cause a reduction in intracel-
lular and an increase in extracellular lactate concentrations. Of
note, solely on day 3, we observed that lactate concentrations
were higher before climbing than after climbing (as shown
in Table 1). There are two possible explanations. First, the
reason for this observation might be many missing values of
lactate level at the peak of Mount Damavand, which should
be considered a shortcoming of this report. The expedition
stayed on the peak only for a few minutes, and measurements
of lactate were done only for 4 patients. Another explanation
could be a “lactate paradox” which defines the phenomenon
of a progressive decrease in plasma lactate when increasing
altitude during maximum effort [22].
Our study has some obvious limitations, such as a small
sample size, gender difference (the majority are men), no
CGMdata available for all patients, and no detailed information
on diet composition. Another issue that should be raised is the
relatively short time of the whole ascent and subsequent lack of
full acclimatization due to the political situation in Turkey
during this investigation (our plane was delayed by one day).
Another important limitation is that all glucose and
lactate monitoring devices were used outside of the range of
their registration altitude and temperature. Relative humidity
might also affect the performance of the devices, but it was
not measured in our study. This makes their accuracy and
precision uncertain and could have influenced the results.
Thus, results obtained in our study must be interpreted with
substantial caution. Of note, this shortcoming concerns most
T1DM observational studies involving biochemical measure-
ments performed at a very high altitude (1, 2, and 3). Further
research is needed to provide a better understanding of the
physiology of high-altitude stress markers, such as catechol-
amines, cortisol, and others.
5. Conclusions
In summary, high mountain trekking is feasible for T1DM
patients with good glycemic control and no chronic compli-
cations. However, some changes in dietary preferences and a
subsequent rise in glucose levels may occur. This requires an
adequate therapeutic response. Our results also seem to
emphasize the necessity of an adequate acclimatization in
this group of patients during high mountain expeditions.
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Figure 1: The relationship between mean glycemia, mean carbohydrate unit intake, and daily insulin dose on each expedition day (with p

































Lactate level at the beginning of day 2 (mmol/L)
p = 0.017
Figure 2: The correlation between lactate concentration at the
beginning of day 2 and mean glucometer glycemia on day 2.
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